Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase i dose-escalation clinical trial

Cytotherapy

Volumn 11, Issue 5, 2009, Pages 653-668

  Van Driessche, Ann ^a,b   Van De Velde, Ann L R ^a,b   Nijs, Griet ^a,b   Braeckman, Tessa ^a   Stein, Barbara ^a,b   De Vries, Jolanda M ^c   Berneman, Zwi N ^a,b   Van Tendeloo, Viggo F I ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Clinical grade manufacturing; Dendritic cells; Immunomagnetic selection; Monocytes; RNA electroporation; Therapeutic vaccines; Wilms tumor WT1

Indexed keywords

CD14 ANTIGEN; DENDRITIC CELL VACCINE; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER PATIENT; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOPRESERVATION; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LEUKAPHERESIS; LYMPHOCYTE; MALE; MONOCYTE; NEPHROBLASTOMA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

ADULT; AGED; CANCER VACCINES; CELL COUNT; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SEPARATION; CELLS, CULTURED; CRYOPRESERVATION; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ELECTROPORATION; FEMALE; FREEZING; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 70849118552     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240902960411     Document Type: Article

References (53)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252
2. Steinman RM, W itmer-Pack M , Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance Adv Exp Med Biol 1993; 329: 1-9.
3. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood J Exp Med 1994 ;180: 83-93.
4. Sallusto F , Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118
5. Caux C, Dezutter DC, Schmitt D, Banchereau J . GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261
6. Siena S , Di Nicola M, Bregni M , Mortarini R, Anichini A, Lombardi L, et al. Massiveex vivo generation of functional dendritic cells from mobilized CD34-blood progenitors for anticancer therapy. Exp Hematol 1995; 23: 1463-1471
7. Rossi M, Young J W. Human dendritic cells: potent antigenpresenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005; 175 : 1373-1381
8. Van Tendeloo V F, P onsaerts P , B erneman Z N. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 2007; 9 : 423-431
9. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, et al. Antigen-specifi c cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863-1871
10. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409
11. Menssen HD, Renkl HJ, Rodeck U, Maurer J , Notter M , Schwartz S, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias . Leukemia 1995; 9: 1060-1067
12. Inoue K , Ogawa H, Sonoda Y , Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-1412
13. Oji Y, O gawa H , Tamaki H, Oka Y , Tsuboi A, K im EH, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth . Jpn J Cancer Res 1999; 90: 194-204
14. Inoue K, Sugiyama H , Ogawa H , Nakagawa M , Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079
15. Oka Y , Tsuboi A, Oji Y, Kawase I, Sugiyama H . WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008 ;20: 211-220
16. Rezvani K , Grube M , Brenchley J M, Sconocchia G , Fujiwara H , Price DA, et al. Functional leukemia-associated antigenspecific memory CD8-T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-2900
17. Rowe JM, Neuberg D, Friedenberg W, Bennett J M, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485
18. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163
19. Scheibenbogen C , Letsch A, T hiel E, S chmittel A , M ailaender V , Baerwolf S, et al . CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2000; 100: 2132-2137
20. Oka Y, Tsuboi A, Taguchi T , Osaki T, Kyo T, Nakajima H, et al Induction of WT1 (Wilms' tumor gene)-specifi c cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890
21. Mailander V , Scheibenbogen C , Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004 ;18: 165-166
22. Rezvani K, Yong AS, Mielke S, Savani B N, Musse L , Superata J, et al. Leukemia-associated antigen-specifi c T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008 ;111: 236-242
23. Barratt-Boyes SM, Figdor CG. Current issues in delivering DCs for immunotherapy . Cytotherapy 2004; 6: 105-110
24. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way . Nat Med 2004 ; 10: 475-480
25. Roddie H, Klammer M , Thomas C, Thomson R , Atkinson A, Sproul A, et al. Phase I/II study of vaccination with dendriticlike leukaemia cells for the immunotherapy of acute myeloid leukaemia . Br J Haematol 2006; 133: 152-157
26. Lee JJ, Choi BH , Kang HK, Kim SK, Nam JH, Yang DH, et al. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specifi c T cells in comparison to leukemic cellderived dendritic cells or monocyte-derived dendritic cells from AML patient. Leuk Res 2008; 32 : 1653-1660
27. Van Tendeloo VF, Ponsaerts P , Lardon F , Nijs G, Lenjou M , Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
28. Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz E S, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defi ned RNAs after rather than before maturation . J Immunol 2005; 174: 3087-3097
29. Cools N , Van Tendeloo VF, Smits EL, Lenjou M , Nijs G , Van Bockstaele DR, et al. Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4-regulatory T cells. J Cell Mol Med 2008 ; 12: 690-700.
30. Kalinski P , Schuitemaker J H , Hilkens CM, Wierenga E A , Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells . J Immunol 1999; 162: 323-16.
31. Vieira PL, D e Jong EC, W ierenga E A, K apsenberg M L, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction . J Immunol 2000 ;164 : 4507-4512
32. Berger TG, Feuerstein B, S trasser E , Hirsch U, Schreiner D , Schuler G, et al. Large-scale generation of mature monocytederived dendritic cells for clinical application in cell factories . J Immunol Methods 2002; 268: 131-140
33. Erdmann M , Dorrie J, Schaft N, Strasser E , Hendelmeier M, Kampgen E , et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and fi nal antigen loading using peptides or RNA transfection. J Immunother 2007 ;30: 663-674
34. Tuyaerts S, Noppe SM, Corthals J, Breckpot K , Heirman C , De Greef C , et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 2002 ; 264: 135-151
35. Houtenbos I , Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia . Immunobiology 2006; 211: 677-685 (Pubitemid 44241640)
36. Jonuleit H , Kuhn U, Muller G , Steinbrink K , Paragnik L , Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27 : 3135-3142
37. Markovic SN , Dietz AB, Greiner CW, Maas ML, Butler G W, Padley DJ, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplifi ed tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med 2006 ; 4 : 35-47.
38. Dietz AB , Padley DJ , Butler GW, Maas ML, Greiner C W , Gastineau DA, et al. Clinical-grade manufacturing of DC from CD14-precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004; 6: 563-570
39. Thurner B , Roder C, D ieckmann D, Heuer M , K ruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application [published erratum appears in J Immunol Methods 1999;224:211]. J Immunol Methods 1999; 223: 1-15.
40. Pickl WF, Majdic O, Kohl P , Stockl J , Riedl E, Scheinecker C, et al. Molecular and functional characteristics of dendritic cells generated from highly purifi ed CD14-peripheral blood monocytes. J Immunol 1996; 157: 3850-3859
41. Faradji A, Bohbot A , Schmitt GM, Siffert JC, Dumont S, Wiesel ML, et al. Large scale isolation of human blood monocytes by continuous fl ow centrifugation leukapheresis and counterfl ow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients. J Immunol Methods 1994 ; 174 : 297-309.
42. Rouard H , Leon A, De Reys S , T aylor L , L ogan J, M arquet J , et al. A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications . Transfusion 2003; 43: 481-487
43. Berger TG, Strasser E , Smith R , Carste C , S chuler-Thurner B, Kaempgen E , et al. Effi cient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells . J Immunol Methods 2005; 298: 61-72.
44. Adamson L, Palmborg A, Svensson A, Lundqvist A , Hansson M, Kiessling R, et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy 2004; 6 : 363-371
45. Kokhaei P, A damson L, Palma M , Osterborg A , P isa P, Choudhury A, et al. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors. Cytotherapy 2006; 8: 318-326
46. Babatz J, R ollig C , O elschlagel U , Z hao S, E hninger G , Schmitz M, et al. Large-scale immunomagnetic selection of CD14-monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res 2003; 12: 515-523 . Dietz AB , Padley DJ
47. Dietz AB , Padley DJ ,Butler GW, Maas M L, G reiner C W , Gastineau DA, et al. Clinical-grade manufacturing of DC from CD14-precursors: experience from phase I clinical trials in CML and malignant melanoma . Cytotherapy 2004 ;6: 563-570
48. Felzmann T, W itt V , Wimmer D, R essmann G, W agner D , Paul P, et al. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection . Cytotherapy 2003; 5 : 391-398
49. Meyer-Wentrup F , Burdach S . E ffi cacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14-starting populations . J Hematother Stem Cell Res 2003; 12: 289-299
50. Breckpot K, Corthals J , Heirman C, Bonehill A , Michiels A , Tuyaerts S , et al. Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells . Hum Gene Ther 2004; 15: 562-573
51. Elkord E , Williams PE , Kynaston H , Rowbottom AW. Human monocyte isolation methods infl uence cytokine production from in vitro generated dendritic cells. Immunology 2005; 114: 204-212
52. Li L , Giannopoulos K , Reinhardt P , Tabarkiewicz J, Schmitt A, Greiner J, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006; 28: 855-861
53. Fratantoni J C, D zekunov S, S ingh V , Liu LN. A non-viral gene delivery system designed for clinical use Cytotherapy 2003; 5: 208-210